Media headlines about Agile Therapeutics (NASDAQ:AGRX) have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Agile Therapeutics earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned headlines about the specialty pharmaceutical company an impact score of 44.8654274634958 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Agile Therapeutics (NASDAQ:AGRX) traded up $0.15 during trading hours on Thursday, reaching $3.47. 314,241 shares of the company’s stock traded hands, compared to its average volume of 467,150. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.10 and a quick ratio of 4.10. Agile Therapeutics has a 52-week low of $1.93 and a 52-week high of $5.60. The stock has a market cap of $111.79, a P/E ratio of -3.77 and a beta of 2.00.
Agile Therapeutics (NASDAQ:AGRX) last posted its earnings results on Monday, November 6th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.03. sell-side analysts predict that Agile Therapeutics will post -0.97 EPS for the current year.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://stocknewstimes.com/2018/01/18/agile-therapeutics-agrx-earning-somewhat-positive-news-coverage-study-shows.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.